Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 851 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 851 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $75.00, for a total value of $63,825.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at approximately $3,912,975. This represents a 1.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total value of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The shares were sold at an average price of $70.22, for a total value of $526,650.00.

Disc Medicine Trading Down 1.8%

Shares of IRON stock opened at $73.14 on Wednesday. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a market cap of $2.79 billion, a PE ratio of -11.05 and a beta of 0.93. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $69.01 and its two-hundred day moving average is $70.63.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Equities analysts predict that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on IRON. Morgan Stanley raised their target price on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Wedbush restated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after buying an additional 828,248 shares during the period. BVF Inc. IL bought a new position in shares of Disc Medicine during the 4th quarter worth about $51,616,000. Jennison Associates LLC acquired a new stake in shares of Disc Medicine during the 4th quarter valued at about $42,252,000. Perceptive Advisors LLC acquired a new stake in shares of Disc Medicine during the 4th quarter valued at about $35,794,000. Finally, RA Capital Management L.P. increased its stake in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after acquiring an additional 399,026 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.